Pancreatic cancer has long been notorious for its aggressive nature and resistance to conventional therapies. One contributing factor is the dense immunosuppressive tumor microenvironment that includes a myriad of immune cells, among which tumor-associated neutrophils (TANs) play a crucial, yet poorly understood, role. These neutrophils, often hijacked by cancer cells, contribute to tumor progression, metastasis, and resistance to treatments. Understanding the molecular pathways that regulate their infiltration into pancreatic tumors has been a critical challenge until now.

At the heart of this study is the newly characterized cellular phenomenon dubbed “cuproplasia,” a copper-dependent cellular proliferation mechanism. Copper, traditionally known as a vital micronutrient involved in angiogenesis and enzymatic reactions, has now been implicated in the regulation of immune cell dynamics within tumors. The researchers discovered that by blocking cuproplasia, they could effectively curtail the recruitment of TANs, significantly impacting tumor progression.

The team employed rigorous in vitro and in vivo models, demonstrating that the inhibition of cuproplasia leads to the downregulation of a pivotal signaling cascade: the TRAF6/STAT3/CCL2 pathway. This axis is known for orchestrating inflammatory responses and mobilizing immune cells toward tissue damage or tumor sites. Specifically, TRAF6 (TNF receptor-associated factor 6) acts as an adaptor protein facilitating STAT3 (signal transducer and activator of transcription 3) phosphorylation, which in turn upregulates the chemokine CCL2, a chief recruiter of neutrophils to the tumor microenvironment.

By employing pharmacological inhibitors and genetic knockdown techniques targeting components of the cuproplasia machinery, the researchers observed a pronounced reduction in STAT3 activation and subsequent CCL2 expression. This molecular blockade resulted in decreased neutrophil infiltration into pancreatic tumors, thereby mitigating the immunosuppressive and pro-tumorigenic milieu that these immune cells typically sustain.

Importantly, this study provides compelling evidence that interfering with cuproplasia not only disrupts neutrophil recruitment but also enhances the efficacy of immune checkpoint blockade therapies. This synergism suggests that targeting copper-dependent proliferative pathways might sensitize tumors to immunotherapies that have historically shown limited success in PDAC patients, both by reducing immunosuppressive forces and fostering a more favorable microenvironment for T-cell mediated tumor eradication.

In elaborating the mechanistic underpinnings, the researchers detailed how cuproplasia impacts mitochondrial metabolism and reactive oxygen species (ROS) production. Copper ions modulate mitochondrial respiratory complexes, promoting metabolic states conducive to cancer cell survival and immune modulation. Inhibiting cuproplasia shifts this balance, perturbing STAT3 signaling cascades, and ultimately modulating chemokine secretion profiles critical for neutrophil homing.

Beyond the immediate findings, the implications of targeting metal ion-dependent cellular processes redefine therapeutic paradigms in oncology. Whereas previous efforts focused primarily on targeting genetic mutations or blocking receptor signaling, this approach centers on exploiting metal homeostasis—a facet often overlooked yet fundamentally intertwined with cellular survival and immune interactions.

The discovery also opens new investigative avenues into the role of cuproplasia in other tumor types characterized by prominent neutrophil infiltration and inflammatory microenvironments. Understanding whether similar copper-dependent mechanisms underlie neutrophil dynamics in lung, breast, or colorectal cancers may vastly expand the clinical applicability of cuproplasia inhibitors.

Clinically, the study’s findings underscore the potential of repurposing existing copper modulation agents, such as copper chelators or inhibitors of copper-dependent enzymes, in combination with immunotherapy regimens for improved patient outcomes. This strategy is particularly promising given the limited therapeutic options presently available to pancreatic cancer sufferers, who often face dismal prognoses.

As the field moves forward, comprehensive characterization of cuproplasia-related biomarkers may become integral in patient stratification, enabling precision medicine approaches to identify individuals most likely to benefit from combined copper-targeted and immunotherapeutic interventions. Moreover, monitoring TRAF6, STAT3, and CCL2 expression patterns could serve as actionable indicators of treatment response and disease progression.

The research further invites a reevaluation of the complex role of copper in tumor biology—from a nutritional cofactor to a master regulator of tumor-immune crosstalk. Insights gained here illuminate the previously uncharted terrain of metallobiology intersecting with immuno-oncology, highlighting a nuanced interplay that could revolutionize therapeutic modalities.

Ultimately, the identification and successful disruption of the cuproplasia-driven TRAF6/STAT3/CCL2 axis represent a significant leap forward in understanding how tumor-associated neutrophils contribute to pancreatic cancer pathogenesis. This work charts a promising course toward novel interventions that may someday transform the grim landscape faced by patients afflicted with this devastating disease.

Subject of Research:
The study investigates the role of cuproplasia in regulating tumor-associated neutrophil infiltration in pancreatic cancer through the TRAF6/STAT3/CCL2 signaling pathway.

Article Title:
Blockage of cuproplasia inhibits pancreatic tumour-associated neutrophils infiltration through TRAF6/STAT3/CCL2 pathway.

Article References:
Geng, R., Cai, H., Ji, X. et al. Blockage of cuproplasia inhibits pancreatic tumour-associated neutrophils infiltration through TRAF6/STAT3/CCL2 pathway. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03371-8

Image Credits:
AI Generated

DOI:
14 April 2026

Pancreatic cancer, notoriously aggressive and resistant to many treatments, has been linked historically to genetic mutations that enable tumor cells to evade normal cellular controls. However, the latest research led by Andrew Feinberg, M.D., a Bloomberg Distinguished Professor at Johns Hopkins University, challenges this paradigm by demonstrating that epigenetic alterations — chemical modifications to DNA and its packaging that influence gene activity — underlie the metastatic process. Feinberg’s prior work in 2017 had already indicated widespread epigenetic changes in metastatic tumors, but the current study elucidates specific molecular players and mechanisms that enforce these alterations.

Central to the study is the use of CRISPR genome-editing technology to methodically silence candidate genes within laboratory-grown human pancreatic cancer cells. By targeting and disabling genes one by one, the team identified KLF5 as a master regulator whose decreased expression resulted in a significant inhibition of metastatic cell growth and migration. This gene’s heightened activity was observed in metastatic lesions from the majority of patients studied, underscoring its critical role. The findings thus direct attention to KLF5 as a potential therapeutic target for halting the dissemination of pancreatic tumors.

Further experimentation revealed that KLF5 influences the architecture of chromatin—the complex of DNA and proteins that packages genetic material within the nucleus. Chromatin organization dictates whether genes are accessible for transcription or repressed, and KLF5 appears to modulate this packaging to selectively activate genes that enhance cancer cell invasiveness. This epigenetic control mechanism enables metastatic cells to thrive and colonize new tissues despite the absence of new DNA mutations, a revelation that redefines cancer progression models.

Intriguingly, subtle variations in KLF5 expression produced disproportionately large effects on the metastatic phenotype, suggesting a non-linear relationship between gene activity and tumor aggressiveness. Feinberg notes that this characteristic could allow for therapeutic strategies aimed at partial inhibition of KLF5, potentially curbing metastasis without necessitating full gene silencing, which might reduce side effects and resistance emerging from complete blockade.

The researchers also identified downstream targets of KLF5, including two epigenetic modifier genes, NCAPD2 and MTHFD1. These genes contribute to the remodeling of DNA packaging and further enhance the malignant capabilities of metastatic cells. Notably, the differential regulation of these modifiers in metastatic versus primary tumor cells hints at a complex epigenetic cascade orchestrated by KLF5 that drives the transition from localized tumors to widespread disease.

This research amplifies the growing consensus in oncology that cancer metastasis should not be viewed solely through the lens of genetic mutations. Instead, layered epigenetic alterations govern the cellular plasticity required for tumor cells to invade, migrate, and establish secondary tumors. By mapping this epigenetic landscape, the Johns Hopkins team is charting new territory for precision medicine, aiming to develop drugs that disrupt these reversible molecular changes without relying exclusively on targeting immutable DNA mutations.

Graduate researcher Kenna Sherman, the study’s first author, emphasizes that KLF5 functions as a ‘master gene’, coordinating a suite of epigenetic factors critical for cancer cell invasion and resistance to conventional treatments. These insights deepen our understanding of the molecular underpinnings of metastasis and open new avenues for designing therapies that could improve survival rates for pancreatic cancer patients, who currently face grim prognoses.

Funded partly by the National Institutes of Health and supported by collaborations across Johns Hopkins, Yale University, and NYU Langone Health, this study exemplifies integrative efforts to tackle one of the deadliest malignancies. With several KLF5-targeting compounds already in development, the translational potential of these findings is immense, promising novel therapies that might prevent or even reverse metastatic spread.

This research, published in the journal Molecular Cancer, exemplifies the shift in cancer research towards appreciating the epigenetic dimension of tumor biology. It underscores the necessity of multifaceted approaches that address gene regulation complexities, chromatin dynamics, and cellular microenvironments to outmaneuver pancreatic cancer’s lethal progression.

The Johns Hopkins team’s investigation thus unveils an epigenetic master switch driving metastasis, with KLF5 at its core—ushering in a new era where targeted modulation of gene expression patterns may curtail the spread of pancreatic and possibly other cancers, transforming patient outcomes globally.

Subject of Research: Pancreatic cancer metastasis and epigenetic regulation involving the gene KLF5

Article Title: KLF5 Drives Pancreatic Cancer Metastasis through Epigenetic Remodeling of Gene Expression

News Publication Date: Not specified

Web References:
– Molecular Cancer article: https://link.springer.com/article/10.1186/s12943-026-02575-z
– Nature Genetics 2017 research: https://www.nature.com/articles/ng.3753

References: DOI 10.1186/s12943-026-02575-z

Image Credits: Andrew Feinberg laboratory, Johns Hopkins Medicine. Originally published in Molecular Cancer

Keywords: Pancreatic cancer, metastasis, epigenetics, KLF5, chromatin remodeling, gene regulation, CRISPR, NCAPD2, MTHFD1